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Omeprazole is a proton pump inhibitor used in the treatment of peptic ulcer disease and gastrosophageal reflux
disease and acts by irreversibly blocking ATP4A, a P-type Hþ /Kþ ATPase in gastric parietal cells. We found that
omeprazole and its closely related congeners inhibited melanogenesis at micromolar concentrations in B16
mouse melanoma cells, normal human epidermal melanocytes, and in a reconstructed human skin model.
Omeprazole topically applied to the skin of UV-irradiated human subjects significantly reduced pigment levels
after 3 weeks compared with untreated controls. Omeprazole had no significant inhibitory effect on the activities
of purified human tyrosinase or on the mRNA levels of tyrosinase, dopachrome tautomerase, Pmel17, or MITF
mRNA levels. Although melanocytes do not express ATP4A, they do express ATP7A, a copper transporting P-type
ATPase in the trans-Golgi network that is required for copper acquisition by tyrosinase. ATP7A relocalization from
the trans-Golgi network to the plasma membrane in response to elevated copper concentrations in melanocytes
was inhibited by omeprazole. Omeprazole treatment increased the proportion of EndoH sensitive tyrosinase,
indicating that tyrosinase maturation was impaired. In addition, omeprazole reduced tyrosinase protein
abundance in the presence of cycloheximide, suggestive of increased degradation. Our findings are consistent
with the hypothesis that omeprazole reduces melanogenesis by inhibiting ATP7A and by enhancing degradation
of tyrosinase.
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INTRODUCTION
Excess production of melanin, and/or its abnormal distribu-
tion, can cause irregular hyperpigmentation of the skin,
leading to melasma, solar lentigenes, age spots, and general
uneven skin color. Melanin synthesis is regulated by the rate-
limiting enzyme, tyrosinase, a copper-containing glycopro-
tein that catalyzes the hydroxylation of tyrosine to dihydrox-
yphenylalanine (DOPA). There is great interest in topical
products for reducing undesirable hyperpigmentation, and
many have been developed that inhibit tyrosinase or have
subsequent reactions in the melanin synthetic pathway (Ando
et al., 2010). As a result of high-throughput screening of
indoles and imidazoles for inhibition of melanogenesis, we
identified a group of proton pump inhibitors with the
pharmacophore 2-pyridylmethylsulfinylbenzimidazole that
inhibited melanin synthesis in mouse melanoma B16F10
cells. Omeprazole is the prototype and best characterized
of that group. This class of proton pump inhibitors acts by
irreversibly blocking the Hþ /Kþ ATPase of the gastric
parietal cells (Roche, 2006), a type II P-type ATPase
encoded by the ATP4A gene. In the acidic environment of
the stomach, omeprazole undergoes molecular rearrange-
ment, exposing a reactive imidazole that covalently binds to
a conserved cysteinyl sulfur moiety of the ATPase and inhibits
its activity. However, expression of the ATP4A gene is
undetectable in melanocytes, suggesting that an alternative
target of omeprazole exists in this cell type.
We then considered the possibility that omeprazole might
block melanogenesis by interfering with an alternative P-type
ATPase, ATP7A, which is required to deliver copper to
tyrosinase within the secretory pathway (Setty et al., 2008).
The ATP7A protein is a ubiquitous regulator of cellular copper
homeostasis and serves two critical functions within cells.
The first involves the supply of copper to copper-dependent
enzymes within the trans-Golgi network, its steady-state
location within the cell. The second function is the export of
excess copper from the cytoplasm, a process that is coupled
with trafficking of the protein from the trans-Golgi network
to post-Golgi vesicles and/or the plasma membrane (Petris
et al., 1996). Mutations in the ATP7A gene that prevent
copper transport activity cause Menkes disease, a copper
deficiency disorder whose symptoms include hypopigmen-
tation due to deficiency in ATP7A-dependent copper delivery
to tyrosinase. Therefore, we examined omeprazole effects on
ATP7A function.
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RESULTS
Effect of omeprazole on melanogenesis in cultured B16F10
melanoma cells and normal human epidermal melanocytes
We confirmed the initial high-throughput B16F10 melanoma
cell screening observation by treating two human cell culture
model systems with omeprazole. To test the omeprazole dose
required for pigment-suppressing activity, we added a range
of nontoxic omeprazole concentrations to the medium of
cultured primary human melanocytes, as well as a melano-
derm skin model. As shown in Figure 1, melanogenesis was
inhibited without cytotoxicity at concentrations of omeprazole
between 7.2 and 150mM in B16F10 melanoma cells
(Figure 1a) and betweenB15 and 30mM in the normal human
epidermal melanocyte (NHEM) model (Figure 1b). In mono-
layer melanocyte cultures, decreased levels of melanin were
evident by 72 hours of treatment, whereas no significant
decreases were evident at 12, 24, and 48 hours (data not
shown). Closely related congeners, including esomeprazole,
lantoprazole, pantoprazole, rabeprazole, and tenatoprazole,
were also found to inhibit melanogenesis of B16F10 melano-
cytes, albeit with higher cytoxicity compared with omeprazole
(Supplementary Figure S1 online). Using a melanoderm
model, omeprazole was found to exhibit a more potent hypo-
pigmentation effect compared with kojic acid (KA), a widely
studied skin lightening agent (Figure 1c).
Effect of omeprazole on UVR-induced pigment development in
human skin
We then investigated whether topical application of omepra-
zole could inhibit UV-induced melanogenesis in the skin of
human subjects. Omeprazole was applied to nonoverlapping
regions of the lower back of 10 individuals at four different
concentrations, along with 2% KA as a positive control.
Exposure to UV light was then used to stimulate pigmentation,
and skin reflectance was measured over a period of 28 days.
As shown in Figure 2, all doses of omeprazole significantly
reduced skin reflectivity (DL* value) compared with untreated
areas and with greater efficacy compared with KA.
Effect of omeprazole on tyrosinase activity
We then explored mechanisms for this anti-melanogenic
effect. Analysis of cell-associated tyrosinase hydroxylase
activity from B16F10 cells incubated with omeprazole for
48 hours indicated that omeprazole induced a dose-depen-
dent decrease in tyrosinase activity (Figure 3a), and this was
associated with a reduction in tyrosinase protein abundance
(Figure 3b). Treatment of B16F10 cells with 50mM omeprazole
for 72 hours decreased tyrosinase protein level to B50% that
of control cells (Figure 3b). These effects of omeprazole
required at least 48 hours of treatment—6- and 24-hour
incubation failed to significantly reduce tyrosinase activity
(data not shown). Figure 3c shows in situ tyrosinase activity
measured in B16 cells under the conditions shown. Treatment
of these melanocytes with 50, 100, and 200mM omeprazole
significantly decreased tyrosinase activity relative to untreated
control or DMSO-treated cells.
Omeprazole failed to demonstrate significant inhibitory
activity on semi-purified tyrosinase (Supplementary Figure
S2a and S2b online), nor did it alter mRNA levels of other
melanogenesis-related proteins such as MITF, DCT, and
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Figure 1. The effect of omeprazole on melanin and cell number in (a) B16F10 mouse melanoma cells, (b) normal human epidermal melanocytes, and (c) a
reconstructed human skin model. Cells were seeded and grown in the appropriate media for the respective cell types. They were then treated with the indicated
concentrations of omeprazole or kojic acid (KA) for 6 days (a, b) or 14 days (c) and assessed for melanin content and cell number. Eumelanin content (closed bar)
and cell viability (open bar) were determined for the reconstructed skin model. The results shown are the average of three determinations±SEM. **Po0.01 versus
vehicle. In addition, reconstructed skin was processed and sectioned tissue was stained by Fontana-Masson stain for melanin. In (c) bar¼ 300mm. OPZ, omeprazole.
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Pmel17 (Supplementary Figure S3 online). This decrease in
tyrosinase protein without a change in transcript levels would
suggest reduced maturation or increased degradation, possibly
due to destabilization of the protein. Instability would result in
increased degradation or reduced processing to the mature
form. Therefore, we examined the effect of omeprazole on
tyrosinase degradation and maturation.
The effect of omeprazole on tyrosinase degradation and
maturation
Omeprazole treatment of NHEM cells resulted in an increased
proportion of EndoH-sensitive tyrosinase to PGNaseF-sensitive
tyrosinase (Supplementary Figure S4 online). Sensitivity to
EndoH digestion is typically associated with a failure to
modify glycans in the Golgi, a process that is known to
depend, at least in part, on copper binding to tyrosinase
(Olivares et al., 2003). ATP7A is located in the Golgi; hence, it
is possible that the increase in sensitivity to EndoH is due to
the reduction in the ability of the cell to perform glycan
modification in the Golgi if tyrosinase is not transiently bound
to copper. Interestingly, omeprazole treatment also increased
tyrosinase degradation (Supplementary Figure S5 online).
Taken together, these results are consistent with a model
whereby omeprazole affects glycan modification and steady-
state abundance of tyrosinase, possibly by interfering with
metallation of the enzyme.
The effect of omeprazole on melanocyte ATPases
Because the endogenous target of omeprazole, ATP4A, is not
expressed in either B16F10 or NHEM (data not shown), we
considered the possibility that omeprazole might inhibit
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Figure 2. The effect of omeprazole on solar simulated UV light–induced tan
in human subjects. Fitzpatrick skin type III subjects were irradiated with
3.5 minimal erythema doses on the lower back. Using a Minolta chromameter,
the change in L* values (DL*) was determined over time for each irradiated site
by comparison with the unirradiated control site.
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Figure 3. The effect of omeprazole (OPZ) on tyrosinase activity (a, c) and protein level (b) in B16F10 cells. In situ tyrosinase activity (a, c) was measured
after 48 hours treatment with omeprazole. In a, tyrosinase hydroxylase activity was measured according to the method of Zhao and Boissy, 1994. In c, cells
were incubated with L-DOPA to measure tyrosinase conversion of colorless L-DOPA to DOPA-chrome (Petris et al., 2000). B16F10 cells were treated with
omeprazole at the indicated concentrations for 48 hours, and tyrosinase protein levels were analyzed by western blot (b) using the mouse monoclonal
anti-tyrosinase IgG antibody T311 (1:120 dilution). The band intensities of tyrosinase were normalized by the band intensities of GAPDH, as an internal control
for each condition. The results shown are the average of three determinations±SEM. Bars¼30mm. *Po0.05, **Po0.01 versus DMSO.
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proteins with structural similarity to the ATP4A proton
pump. Therefore, we considered other ATPases, namely
ATP7A and ATP12A, as potential candidates. Using reverse
transcriptase–PCR, we found both ATPases to be expressed in
NHEM and B16 melanoma cells (data not shown). We further
found that the ATP12A inhibitor, ouabain, did not inhibit
melanogenesis, thus excluding ATP12A as a likely target of
omeprazole. In contrast, ATP7A was considered a more likely
candidate, as it belongs to the same superfamily of P-type
ATPases as ATP4A, and is necessary for copper delivery to
tyrosinase in the secretory pathway (Petris et al., 2000; Setty
et al., 2008).
Omeprazole inhibits ATP7A-dependent activation of tyrosinase
To examine the possible effects of omeprazole on ATP7A
function, we tested whether omeprazole might inhibit the
ability of recombinant ATP7A to transport copper to tyrosinase
in Menkes patient fibroblast cells, which lack endogenous
ATP7A (La Fontaine et al., 1998; Petris et al., 2000). In the
present study, Menkes fibroblasts were pretreated with
omeprazole or DMSO overnight prior to transfection with a
tyrosinase expression plasmid alone or in combination with an
ATP7A plasmid. Cells were incubated for 24 hours to allow
plasmid expression in the continued presence of DMSO or
omeprazole, and then tyrosinase activity was assayed in situ.
As shown in Figure 4a and b, transfection of Me32a cells with
the tyrosinase plasmid alone failed to produce DOPA oxidase
activity in cells treated with either DMSO or omeprazole.
However, co-transfection of both tyrosinase and ATP7A
resulted in abundant tyrosinase activity in the DMSO-treated
cells (Figure 4c), but there was a marked diminution of
tyrosinase activity in the omeprazole-treated doubly trans-
fected cells (Figure 4d). Densitometry analysis of the ATP7Aþ
Tyr-transfected population of cells demonstrated that omepra-
zole significantly reduced the average intensity of
dopachrome staining almost 2-fold (from 228.71±35.91
(SEM) to 126.64±10.70 (SEM); n¼ 25 cells; Po0.01; Stu-
dent’s t-test). There was no difference in cell viability between
omeprazole- and DMSO-treated cells.
Omeprazole inhibits copper-stimulated trafficking of ATP7A
The above findings support the concept that, in addition to
enhancing tyrosinase degradation, omeprazole might inhibit
copper transport to tyrosinase via the ATP7A protein. To
further evaluate ATP7A as a potential target of omeprazole,
we investigated whether omeprazole might block ATP7A
trafficking. The ATP7A relocalizes from the trans-Golgi
network to the plasma membrane in response to elevated
copper concentrations, as a mechanism to export excess
copper. Importantly, this copper-stimulated trafficking of
ATP7A is dependent on its catalytic activity, as catalytically
dead mutants of ATP7A cannot undergo copper-stimulated
trafficking (Petris et al., 2002). Accordingly, we reasoned that
if the inhibitory effect of omeprazole on melanogenesis was
occurring through inhibition of ATP7A-mediated copper
transport to tyrosinase, omeprazole should also impair
copper-stimulated trafficking of ATP7A from the trans-Golgi
network. B16F10 melanoma cells were treated for 16 hours
with 0.1% DMSO alone or the same solvent containing 50mM
or 100mM omeprazole. Copper (10mM) was then added for 3
hours to half of the samples to elicit ATP7A trafficking prior to
immunofluorescence analysis of ATP7A. The distribution of
the ATP7A protein in cells exposed to DMSO or omeprazole
without added copper was similar to the Golgi marker protein
GM130, demonstrating that omeprazole does not affect basal
localization of ATP7A (Figure 5a–c). As expected, the addition
of 10mM copper to the DMSO-treated cells for 3 hours elicited
robust trafficking in ATP7A localization to the cell periphery
(Figure 5d–f). However, this trafficking effect was partially
suppressed in cells exposed to 50mM omeprazole (Figure 5j–l)
TYR (DMSO) TYR+ATP7A 
(+DMSO)
TYR+ATP7A 
(+omeprazole)
TYR (OPZ)
Figure 4. The effect of omeprazole on tyrosinase activity on ATP7A-dependent tyrosinase activity in Menkes patient fibroblasts. Me32a cells were pretreated
overnight with DMSO (a, c) or omeprazole (100mM) (b, d) and then transiently transfected with tyrosinase expression plasmid (pTYR) alone (a, b) or in combination
with a plasmid encoding human ATP7A (c, d). Cells were allowed to recover for 24 hours in the continued presence of DMSO or omeprazole. In situ tyrosinase
activity was then measured as in Figure 3c. Bars¼30mm.
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and fully suppressed in cells exposed to 100mM omeprazole
(Figure 5m–o). These findings suggest that omeprazole sup-
presses the copper-stimulated trafficking of ATP7A from the
Golgi to the plasma membrane. Shorter pretreatments of
omeprazole (up to 2 hours) failed to block copper-stimulated
trafficking of ATP7A (data not shown).
Omeprazole as a potential copper chelator
Because omeprazole has been shown to interact directly with
copper (Hamdan, 2001), we tested whether omeprazole might
block tyrosinase activity or ATP7A trafficking by chelating
copper. We tested this hypothesis by comparing omeprazole
with bathocuproine disulphonate (BCA), a high-affinity copper
chelator. BCA inhibition of melanogenesis was supressed by
the addition of copper to the media, with no accompanying
cytotoxicity (Figure 6a). A similar set of experiments was
performed with phenylthiourea, another compound that binds
to copper and inhibits tyrosinase and melanogenesis (Hall and
Orlow, 2005). As was the case with BCA, 20mM phenyl-
thiourea significantly decreased melanogenesis in B16F10
cells, an effect that was fully reversed by supplementation
with 40mM CuSO4 (data not shown). A different pattern
emerged with omeprazole (Figure 6b). Increasing the level
of copper in the presence of omeprazole only partially
restored the ability to synthesize melanin but markedly
decreased cell viability. Because ATP7A trafficking to the
plasma membrane is necessary for exporting potentially high
levels of toxic copper, inhibition of ATP7A trafficking by
omeprazole is a likely explanation for this hypersensitivity to
copper.
DISCUSSION
The data described here identify omeprazole and its congeners
as small molecule inhibitors of melanogenesis in cells and
human skin. Our findings, taken as a whole, are consistent
with the hypothesis that omeprazole inhibits metallation of
newly synthesized tyrosinase via ATP7A. Whether omepra-
zole is a direct inhibitor of ATP7A or indirectly impacts this
protein is not determined by our study. However, omeprazole
does not appear to function as a direct inhibitor of tyrosinase
per se or by acting as a copper chelator. This is supported by
several lines of evidence. First, we were unable to detect any
ATP7A GM 130 Overlay
DMSO
DMSO (16 h)
+ Cu 10 μM (3 h)
50 μM OPZ  (16 h)
50 μM OPZ (16 h)
+ 10 μM Cu (3 h)
100 μM OPZ (16 h)
+ 10 μM Cu (3 h)
Figure 5. The effect of omeprazole on copper-induced trafficking of ATP7A in B16F10 cells. Cells were exposed for 16 hours to 50 or 100mM omeprazole
dissolved in DMSO or DMSO alone. CuCl2 (10mM) was then provided to cells for 3 hours to induce relocalization of ATP7A into cytoplasmic vesicles. Treatment
conditions are indicated to the left of Figure 5. Cells shown in a–c were treated with DMSO as control, d–f with DMSO and 10mM CuCl2, g–i with 50mM OPZ in
DMSO, j–l with 50mM OPZ for 16h and then 10mM CuCl2 for 3h, and m–o with 100mM OPZ for 16h and then 10mM CuCl2 for 3h. Cells were fixed,
permeabilized, and probed with antibodies to detect ATP7A (green). Nuclei were labeled with DAPI (blue), and Golgi were labeled with the Golgi marker GM130
(red). The figure is representative of three separate experiments. Scale bars ¼ 10mm. OPZ, omeprazole.
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direct inhibition of omeprazole toward purified tyrosinase.
Second, we found that 48- to 72-hour exposure time was
required to detect significant inhibition of melanogenesis in
cultured melanocytes. Such a time lag is not consistent with a
mode of activity that involves direct inhibition of tyrosinase or
copper chelation. Rather, these observations are consistent
with a model in which omeprazole inhibits newly synthesized
tyrosinase, with the delay in its effects due to the requirement
for the turnover of preexisting tyrosinase. It is also possible that
these delayed effects of omeprazole may reflect the time
required to reach inhibitory concentrations within specific
organelles such as the luminal compartments of the Golgi or
the melanosome. Alternatively, omeprazole may undergo
activation by molecular rearrangement before it can bind to
its target. The finding that omeprazole partially suppressed
ATP7A-dependent activation of tyrosinase in Menkes patient
cells and blocked trafficking of ATP7A from the Golgi to the
plasma membrane supports a model in which omeprazole
prevents melanogenesis in part by blocking ATP7A copper
transport activity. Trafficking of ATP7A to the cell membrane
following stimulation of cells with copper is a process that is
intrinsically dependent on ATP7A catalytic activity (Petris
et al., 2002), underscoring the possibility that omeprazole
may directly bind to ATP7A. Omeprazole is known to inhibit
the gastric ATPase through binding to a luminal cysteine
between the fifth and sixth transmembrane domains. Although
this sequence is not conserved in ATP7A, it is possible that
cysteines, which are essential for transport activity, such as the
canonical CPC motif within the sixth transmembrane domain,
might serve as potential binding sites of omeprazole. It should
be noted that a potential binding site on ATP7A for
omeprazole has been reported (Lambrecht et al., 1998).
Our data cannot formally exclude the possibility that
omeprazole acts indirectly to block ATP7A through binding
to an intermediary protein. Indeed, the effects of omeprazole
on ATP7A, together with the finding that omeprazole reduced
the fraction of EndoH resistant, stably glycosylated tyrosinase
and decreased tyrosinase abundance in cycloheximide-treated
cells, are consistent with more than one mechanism of action.
Previous studies have shown that tyrosinase abundance is not
reduced by a lack of copper insertion (Petris et al., 2000; Setty
et al., 2008), suggesting that the effects of omeprazole on
tyrosinase protein levels are not a consequence of ATP7A
inhibition, underscoring the possibility that additional, as yet
unknown pathways involving tyrosinase expression or stability
are also affected.
An important implication of our findings is the potential to
repurpose omeprazole as a topical inhibitor of pigmentation
in vivo. Currently, omeprazole is administered as an oral
treatment for gastroesophageal reflux disease and gastric
hyperacidity. This pathway of administration has only rarely
and not consistently been associated with effects on pigmen-
tation, probably because the acid space–dependent concen-
tration of proton pump inhibitors is the first important property
that determines their therapeutic index, giving a concentration
at the luminal surface of the pump that is about 1,000-fold
higher than in the blood. Thus, a lack of reported pigmentary
side effects of orally administered omeprazole is most likely
due to the localized activation and retention of the drug in
the acidic stomach and the failure to accumulate sufficient
concentrations in the skin that would permit blockage of
pigmentation.
Our results are in agreement with recent findings that
rabeprazole and lansoprazole exacerbated vitiligo symptoms
in two patients (Shin et al., 2013). This study further showed
that 50–100mg ml1 pantoprazole decreased melanin content
and tyrosinase activity in B16 murine melanoma cells, as well
as a zebrafish model; however, the mechanism of these effects
was not delineated. Our study presents a new paradigm for the
localized effect of the omeprazole family of proton pump
inhibitors on melanogenesis, in part by the blocking ATP7A-
dependent transport of copper to tyrosinase. On a broader
scale, small molecule inhibitors of ATP7A may be represent a
unique, and to our knowledge not previously recommended,
approach to treat disorders in which upregulation of ATP7A
has been associated such as Alzheimer’s disease (Zheng et al.,
2010) and the resistance to cancer chemotherapy (Leonhardt
et al., 2009).
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Figure 6. The effect of copper addition to B16F10 cells treated either with a
high-affinity copper chelator (a) or with omeprazole (b). Cells were grown in
the appropriate medium in the presence of fetal bovine serum and 2.0 mM
theophylline and treated with either bathocuproine disulphonate (BCA) or
omeprazole for 72 hours at the concentrations shown. Cell number is shown
by the light bars, melanin content by the dark bars.
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MATERIALS AND METHODS
Effect on melanin synthesis and cell growth in B16F10 mouse
melanoma cells and normal human epidermal melanocytes
(NHEMs)
B16F10 mouse melanoma cells and NHEMs were grown in DMEM
(Sigma, St Louis, MO) containing 10% fetal bovine serum (Hyclone)
and Medium 254 with human melanocyte growth supplement
(Kurabo, Osaka, Japan), respectively. After 18 hours, the cells were
treated with a medium containing 2.0 mM theophylline and treatment
agents, as described for individual experiments and incubated for 3
days. Mouse melanoma cells were seeded into 12-well plates at a
concentration of 1.0 104 cells per well. NHEMs were seeded in
culture dishes at 1.2 105 cell per 6-well dish. After 18 hours, the
cells were treated with a medium containing treatment agents, as
described for individual experiments for 6d. Medium was changed on
day 2 and day 4 to the same medium containing sample compounds.
Cells were harvested by 0.05% trypsin-EDTA, and the amount of
protein in the cell lysate was determined using the BCAtprotein assay
kit (Thermo, Waltham, MA). Cells were then washed twice
with phosphate-buffered saline( ) and treated with 10% trichloroa-
cetic acid for 15 minutes at 4 1C and with ethanol-ether 1:1 (v/v) at
room temperature for 10 minutes. After discarding the organic
solvent, the dried cells were solubilized in 1 N NaOH/10% DMSO
by incubation at 37 1C for 30 minutes. The absorbance of dissolved
melanin was read at 490 nm using a micro-plate reader (Bio-Rad,
Hercules, CA). Each value of the ratio A490 to protein content was
used for the comparison of intracellular melanin contents. Relative
cell number was determined by the BCA protein assay.
Effect on melanin synthesis and cytotoxicity in a reconstructed
human skin model
The three-dimensional reconstructed human skin (MEL-300-A: co-
culture of normal human melanocytes from Asian donors and normal
keratinocytes) was purchased from Kurabo. The effect of omeprazole
and KA on melanin synthesis and cytotoxicity was evaluated by
applying to the surface of the skin model: 50ml of 10% propylene
glycol (vehicle), 50ml of 145mM or 290mM omeprazole, or 50ml of
7 mM of KA. The tissue was incubated for 14 days. The culture
medium (LLMM) and test solutions were renewed on alternate days.
Cell viability and eumelanin content were determined by the MTT
assay kit (Kurabo) and the alkaline H2O2 oxidation and HPLC assay
(Ito and Wakamatsu, 1998). For cross-sectional observation, the
tissues were washed with phosphate-buffered saline twice and were
fixed in SUPER FIX (Kurabo) overnight at 4 1C. Then, the tissues were
dehydrated in a graded series of ethanol, embedded in paraffin, and
7-mm cross sections were cut. After deparaffinization, the sectioned
tissues were then stained by Fontana–Masson stain for melanin
pigment and Kernechtrot stain for nuclei.
Effect of omeprazole on human skin pigmentation
Test sites of 4 cm2 on 10 female volunteers, 18–45 years of age, of
Fitzpatrick skin type III were irradiated with 3.5 minimal erythema
doses on the lower back from a 150 W xenon arc solar simulator
with UG-5 filters. One site was marked and left unirradiated.
Omeprazole was freshly prepared in ethanol at doses between 0.02
and 0.1% and applied by swabbing once per day for 4 weeks. One
site was treated similarly with 2% KA and one irradiated site was left
untreated. Skin reflectance, L* values, were measured in triplicate
twice per week using a Minolta Chromameter (Minolta, Ramsey, NJ).
To obtain the change in L* values (DL*) for each time point, values
from the unirradiated site were subtracted from each of the other
test sites.
Tyrosinase activity assay
Tyrosinase hydroxylase activity in NHEM extracts was
measured according to the method of Zhao and Boissy (1994).
Briefly, cells were seeded in 12-well plates at a density of 0.5 105
cells per well and cultured overnight. The medium was then changed
to a fresh medium containing the indicated concentrations of
omeprazole. The cells were harvested by trypsin-EDTA, the number
determined by counting chamber, and cell extracts prepared. For
extract analysis, cells were lysed in 0.5% NP40/phosphate-buffered
saline by sonication. Lysates were centrifuged (3,000g) at 4 1C for
10 minutes and supernatants used as sample. In addition, cells were
harvested and cell lysates fractionated by SDS-PAGE in the absence of
reducing agents (Zhao and Boissy, 1994). Tyrosinase activity was
detected in gels via L-DOPA oxidation to DOPA-chrome. In situ in
fixed cells, tyrosinase activity was colorimetrically detected as
previously described by assaying the formation of DOPA-chrome
(dark) from the oxidation of L-DOPA (colorless; Petris et al., 2000).
Effect of omeprazole on mRNA transcripts
Quantitative RT-RCR was used to measure mRNA levels for tyrosi-
nase, dopachrome tautomerase, microphthalmia-associated transcrip-
tion factor (Mitf), and Pmel17. B16 cells plated at a density of
2.5 105 cells per dish. After overnight culture, fresh medium was
added for a further 24 hours containing the indicated concentrations
of omeprazole. Total RNA was isolated using RNeasy Mini (Qiagen,
Osaka, Japan) and cDNA prepared for quantitative reverse
transcriptase–PCR to determine tyrosinase, dopachrome tautomerase,
and Mitf mRNA transcript levels using specific primers and SYBR
green (API, Bio-Rad). Total RNA was isolated using RNeasy Mini
(Qiagen) from NHEM cells treated with the indicated concentrations
of omeprazole. First-strand cDNA was synthesized from total RNA
(0.7mg) by using the ReverTra Ace qPCR RT Kit (TOYOBO, Osaka,
Japan). reverse transcriptase–PCR reaction was performed using
THUNDERBIRD SYBR qPCR Mix (TOYOBO) and 7300 Real-Time
PCR System (Applied Biosystems, Tokyo, Japan) according to the
manufacturer’s specifications. Relative amounts of mRNA were cali-
brated by the amount of GAPDH mRNA in the sample. Primers used
were as follows: MITF: 50-GGAGGGATAGTCTACCGTCTCTCA-30 (F)
and 50-AGTGATTATATTCTAGCATTTCCAGCATAA-30 (R); Tyrosi-
nase: 50-CACCATGCTCCTGGCTG-30 (F) and 50-TTATAAATGGCTC
TGATACAAGCTGTGG-30 (R); dopachrome tautomerase: 50-GGTGC
GAGCCGACACAAG-30 (F) and 50-CCACAGCTCACGGTCATCCT (R);
GAPDH: 50-CCACCCATGGCAAATTCC-30 (F) and 50-TGGGATTTCC
ATTGATGTGACAAG-30 (R).
Effect of omeprazole on tyrosinase maturation and
degradation
To determine the effect of omeprazole on tyrosinase maturation,
measurement of the ratio of EndoH sensitive tyrosinase to PNGase F
was conducted according to Costin et al. (2003). When proteins are
correctly processed through the endoplasmic reticulum and Golgi,
they become resistant to EndoH. Therefore, sensitivity to EndoH
indicates the presence of proteins that have not correctly processed
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beyond the endoplasmic reticulum. By contrast, PNGaseF removes
all carbohydrate residues and reveals the native polypeptide size of
the protein. NHEMs were grown and treated with the indicated
concentrations of omeprazole for 72 hours, as described above for
melanogenesis assays. Cells were harvested and 10mg protein extracts
were heated in glycoprotein denaturing buffer (H and PNGase F) for
10 minutes at 100 1C in final volume of 10ml. The samples were
cooled, briefly centrifuged, and 2000U Endo H or 1000U PNGase F
was added in a final volume of 20ml.The reactants were mixed and
incubated in water bath for 90 minutes at 37 1C. The reactants were
cooled, reduced, and resolved by 4–12 Bis-Tris Nu PAGE gel. The
PAGE resolved proteins were transferred to polyvinylidene difluoride
membrane and probed with specific antibodies at 1:500 for tyrosinase
and 1:1000 GAPDH at 4 1C overnight. The next day, the membranes
were washed, probed with secondary antibody, and signal captured
with the LiCor imaging system, Odyssey CLX (Lincoln, NE). The
provided software was used to quantify band intensity.
To determine the effect of omeprazole on tyrosinase degradation,
NHEMs were plated at a density of 2 106 cells per 10 cm dish 24
hours before treatment with test compounds. The medium was
replaced with that containing the indicated concentrations of ome-
prazole (12.5–75mM) for 72 hours, after which the medium was
refreshed again with corresponding concentrations of omeprazole,
with and without added cycloheximide at a final concentration of
1mg/ml. After 8 hours with cyloheximide, the medium was aspirated;
the cells were washed once with 10 ml of phosphate-buffered saline
and scraped into a tube. The cells were pelleted and protein extracted
by cytobuster supplemented with protease inhibitors (without EDTA)
according to the manufacturer recommendations. A total of 10mg per
well protein was resolved by 4–12% gradient Bis-Tris Nu PAGE under
reducing conditions and transferred to polyvinylidene difluoride
membranes. The membrane was washed, blocked, and incubated
overnight at 4 1C (1:500 for Tyrosinase antibody and 1:1000
GAPDH). The next day, the membranes were washed, probed with
secondary antibody, and the signal was captured with a LiCor
imaging system, Odyssey CLX. The provided software was used to
quantify band intensity.
Tyrosinase assays in transfected Menkes cells
The Menkes fibroblast cell line, Me32a, was transiently transfected
with a tyrosinase expression plasmid alone, or in combination with a
human ATP7A expression plasmid using Lipofectamine 2000, as
previously described (Petris et al., 2000). Cells were incubated in
recovery media containing the indicated omeprazole concentrations,
and in situ tyrosinase activity was measured as previously described
(Petris et al., 2000).
Immunofluorescence microscopy
Immunofluorescence microscopy was performed as previously
described (Petris et al., 2000). ATP7A was detected using affinity-
purified ATP7A antibodies and detected using Alexa488 anti-rabbit
secondary antibodies (Life Technologies, Carlsbad, CA). Antibodies
against GM130 were from BD Transduction Laboratories (San Jose,
CA). Copper as CuCl2 was added to cells at the indicated
concentrations for 3 hours to induce relocalization of ATP7A from
the Golgi.
CONFLICT OF INTEREST
MSM, NK-J, NM, and DBY are full-time employees of The Estee Lauder
Companies. MJP and MI received consulting fees from The Estee Lauder
Companies. YN received financial support in the form of a research grant from
The Estee Lauder Companies.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper at http://
www.nature.com/jid
REFERENCES
Ando H, Matsui MS, Ichihashi M (2010) Quasi-drugs developed in Japan for
the prevention or treatment of hyperpigmentary disorders. Int J Mol Sci
11:2566–75
Costin GE, Valencia JC, Vieira WD et al. (2003) Tyrosinase processing and
intracellular trafficking is disrupted in mouse primary melanocytes
carrying the underwhite (uw) mutation. A model for oculocutaneous
albinism (OCA) type 4. J Cell Sci 116(Pt 15):3203–12
Hall AM, Orlow SJ (2005) Degradation of tyrosinase induced by phenylthiourea
occurs following Golgi maturation. Pigment Cell Res 18:122–9
Hamdan II (2001) In vitro study of the interaction between omeprazole and the
metal ions Zn(II), Cu(II), and Co(II). Pharmazie 56:877–81
Ito S, Wakamatsu K (1998) Chemical degradation of melanins: application to
identification of dopamine-melanin. Pigment Cell Res 11:120–6
La Fontaine SL, Firth SD, Camakaris J et al. (1998) Correction of the copper
transport defect of Menkes patient fibroblasts by expression of the Menkes
and Wilson ATPases. J Biol Chem 273:31375–80
Lambrecht N, Corbett Z, Bayle D et al. (1998) Identification of the site of
inhibition by omeprazole of a alpha-beta fusion protein of the H,K-
ATPase using site-directed mutagenesis. J Biol Chem 273:13719–28
Leonhardt K, Gebhardt R, Mossner J et al. (2009) Biochemical basis of
regulation of human copper-transporting ATPases. Arch Biochem Biophys
463:134–48
Olivares C, Solano F, Garcia-Borron JC (2003) Conformation-dependent post-
translational glycosylation of tyrosinase: requirement of a specific inter-
action involving the CuB metal binding site. J Biol Chem 278:15735–43
Petris MJ, Mercer JF, Culvenor JG et al. (1996) Ligand-regulated transport of the
Menkes copper P-type ATPase efflux pump from the Golgi apparatus to
the plasma membrane: a novel mechanism of regulated trafficking. EMBO
J 15:6084–95
Petris MJ, Strausak D, Mercer JF (2000) The Menkes copper transporter is
required for the activation of tyrosinase. Hum Mol Genet 9:2845–51
Petris MJ, Voskoboinik I, Cater M et al. (2002) Copper-regulated trafficking of
the Menkes disease copper ATPase is associated with formation of a
phosphorylated catalytic intermediate. J Biol Chem 277:46736–42
Roche VF (2006) The chemically elegant proton pump inhibitors. Amer J
Pharma Education 70, Article101
Setty SR, Tenza D, Sviderskaya EV et al. (2008) Cell-specific ATP7A transport
sustains copper-dependent tyrosinase activity in melanosomes. Nature
454:1142–6
Shin JM, Lee JY, Lee DY et al. (2013) Proton pump inhibitors as a possible
cause of vitiligo: an in vivo and in vitro study. J Eur Acad Dermatol
Venereol 28:1475–9
Zhao H, Boissy RE (1994) Distinguishing between the catalytic potential and
apparent expression of tyrosinase activities. Am J Med Sci 308:322–30
Zheng Z, White C, Lee J (2010) Altered microglial copper homeostasis in a
mouse model of Alzheimer’s disease. J Neurochem 114:1630–8
MS Matsui et al.
Omeprazole, ATP7A, and Melanogenesis
www.jidonline.org 841
